SOMATULINE DEPOT (lanreotide acetate)

Office-Administration – subcutaneous (SC) injection

Diagnosis considered for coverage:
  • Acromegaly: Indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The goal of treatment in acromegaly is to reduce growth hormone (GH) and insulin growth factor-1 (IGF-1) levels to normal.
  • Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
  • Carcinoid Syndrome: Indicated for the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.
    • Off Label Use for Lanreotide

 

Coverage Criteria:

For diagnosis of acromegaly:

  • Diagnosis of acromegaly, AND
  • Prescribed by or in consultation with an endocrinologist, AND
  • Trial and failure or intolerance to Somatuline Depot (Applies to Brand Lanreotide only), AND
  • One of the following: 
    • Inadequate response to one of the following:
      • Surgery
      • Radiotherapy
    • Not a candidate for one of the following:
      • Surgery
      • Radiotherapy

For diagnosis of advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET): 

  • Diagnosis of gastroenteropancreatic neuroendocrine tumor (GEP-NET), AND
  • Disease is one of the following: 
    • Unresectable, locally advanced 
    • Metastatic, AND
  • Prescribed by or in consultation with an oncologist, AND
  • Trial and failure or intolerance to Somatuline Depot (Applies to Brand Lanreotide only) 

For diagnosis of carcinoid syndrome:

  • Diagnosis of carcinoid syndrome, AND
  • Used to reduce the frequency of short-acting somatostatin analog rescue therapy, AND
  • Prescribed by or in consultation with an endocrinologist or oncologist, AND
  • Trial and failure or intolerance to Somatuline Depot (Applies to Brand Lanreotide only)

 

Reauthorization Criteria:

For diagnosis of acromegaly:

  • Patient demonstrates positive clinical response to therapy, such as a reduction or normalization of IGF-1/GH level for same age and sex 

For diagnosis of GEP-NET:

  • Patient does not show evidence of progressive disease while on therapy

For diagnosis of carcinoid syndrome: 

  • Patient demonstrates positive clinical response to therapy

 

Coverage Duration: 
  • Initial: 12 months
  • Reauthorization: 12 months

 

Dosing: 

For diagnosis of acromegaly:

  • 90 mg every 4 weeks for 3 months. Adjust thereafter based on GH and/or IGF-1 levels as follows:
    • GH greater than 1 ng/mL to less than or equal to 2.5 ng/mL, IGF-1 normal, and clinical symptoms controlled: maintain dosage at 90 mg every 4 weeks
    • GH greater than 2.5 ng/mL, IGF-1 elevated, and/or clinical symptoms uncontrolled: increase dosage to 120 mg every 4 weeks
    • GH less than or equal to 1 ng/mL, IGF-1 normal, and clinical symptoms controlled: reduce dosage to 60 mg every 4 weeks
  • Patients who are controlled on 60 or 90 mg may be considered for an extended dosing interval of 120 mg every 6 or 8 weeks

For diagnosis of GEP-NET:

  • 120 mg every 4 weeks 

For diagnosis of carcinoid syndrome: 

  • 120 mg every 4 weeks

 

Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information: 
  • If patients are already being treated with Somatuline Depot for GEP-NET, do not administer an additional dose for carcinoid syndrome.
Policy Updates:
  • 09/01/2024 – New policy for Somatuline approved by WHA P&T Committee (P&T, 08/20/2024) 
References:
  1. Somatuline Depot Prescribing Information. Ipsen Biopharmaceuticals, Inc. Cambridge, MA. February 2023. 
  2. Lanreotide Injection Prescribing Information. Cipla USA Inc. Warren, NJ. December 2021. 
  3. Lanreotide Acetate. In: IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www.micromedexsolutions.com/. Accessed September 12, 2023. 

 

 

Last review date: September 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone